SILVER SPRING
Jakafi XR cleared for myelofibrosis, polycythemia vera, GVHD
- Sponsor
- Incyte $INCY
- Drug
- Jakafi XR · ruxolitinib
- Indication
- myelofibrosis, polycythemia vera, graft-versus-host disease
FDA approved Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease in adults.
What this means
Jakafi XR is an extended-release version of ruxolitinib, a pill that blocks overactive immune signals in certain blood disorders and transplant complications. FDA approved the once-daily version for adults with myelofibrosis, polycythemia vera, or graft-versus-host disease who were already using the twice-daily form. The new formulation could make treatment easier by reducing pill burden while maintaining the same active ingredient.
Drug Watch — recent news on Jakafi XR
- Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner? - TradingView
- Incyte stock trades steady as Jakafi revenue supports 2024 outlook - AD HOC NEWS
- Ruxolitinib Shows Efficacy in Atopic Dermatitis - Physician's Weekly
- Incyte stock trades steady as Jakafi revenue grows and pipeline updates shape outlook - Ad-hoc-news.de
- Armistice Capital Holds Incyte as $1.25B Vega Deal Closes, Opzelura Clears EU Panel - The Ritz Herald